Final results of a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin, and pazopanib: 2ND-STEP study, JCOG1802. Phase 1/2 study of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results